Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedFeb 16, 2026
DataAggregated Company Financials
Companies152
  • 7D-2.8%
  • 3M-5.1%
  • 1Y-11.7%
  • YTD-2.9%

Over the last 7 days, the Healthcare industry has dropped 2.8%, driven by Camurus declining 20%. Overall the industry is down 12% in 12 months. As for the next few years, earnings are expected to grow by 25% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 16 Feb 2026SEK 565.4bSEK 230.6b-SEK 1,735,172,894.8930.8x-325.8x2.5x
Wed, 14 Jan 2026SEK 611.3bSEK 230.2bSEK 3.7b42.6x166.6x2.7x
Fri, 12 Dec 2025SEK 588.4bSEK 230.5bSEK 3.5b41.4x166.1x2.6x
Sun, 09 Nov 2025SEK 587.5bSEK 229.8bSEK 2.9b42.7x201.7x2.6x
Tue, 07 Oct 2025SEK 618.9bSEK 227.1bSEK 6.6b43.1x93.7x2.7x
Thu, 04 Sep 2025SEK 615.2bSEK 227.1bSEK 6.6b44.2x93.4x2.7x
Sat, 02 Aug 2025SEK 614.3bSEK 226.9bSEK 6.5b51.4x94x2.7x
Mon, 30 Jun 2025SEK 616.8bSEK 226.8bSEK 5.9b44.9x105.1x2.7x
Wed, 28 May 2025SEK 597.8bSEK 226.2bSEK 6.6b38.4x90.9x2.6x
Fri, 25 Apr 2025SEK 562.5bSEK 222.0bSEK 4.9b37.6x114.9x2.5x
Sun, 23 Mar 2025SEK 556.7bSEK 206.2bSEK 5.0b36.7x110.3x2.7x
Tue, 18 Feb 2025SEK 602.6bSEK 206.5bSEK 2.5b42.4x241.1x2.9x
Thu, 16 Jan 2025SEK 578.6bSEK 202.6b-SEK 2,489,013,482.8042.8x-232.5x2.9x
Sat, 14 Dec 2024SEK 572.3bSEK 202.8b-SEK 2,527,875,410.5838.5x-226.4x2.8x
Mon, 11 Nov 2024SEK 528.0bSEK 200.2b-SEK 2,439,386,725.9538.6x-216.4x2.6x
Wed, 09 Oct 2024SEK 545.6bSEK 196.9b-SEK 3,230,044,283.0738.3x-168.9x2.8x
Fri, 06 Sep 2024SEK 605.7bSEK 200.1b-SEK 2,806,800,946.5739.6x-215.8x3x
Sun, 04 Aug 2024SEK 569.5bSEK 199.6b-SEK 2,762,712,499.7440.4x-206.1x2.9x
Tue, 02 Jul 2024SEK 564.0bSEK 195.8b-SEK 3,202,769,986.2638.5x-176.1x2.9x
Thu, 30 May 2024SEK 548.4bSEK 196.0b-SEK 2,831,889,538.7635.8x-193.6x2.8x
Sat, 27 Apr 2024SEK 530.8bSEK 196.4b-SEK 3,453,297,186.6237.2x-153.7x2.7x
Mon, 25 Mar 2024SEK 519.8bSEK 192.7b-SEK 3,668,823,382.9843.3x-141.7x2.7x
Wed, 21 Feb 2024SEK 516.1bSEK 191.7b-SEK 4,108,827,824.1949.5x-125.6x2.7x
Fri, 19 Jan 2024SEK 544.3bSEK 191.8b-SEK 969,144,311.0050x-561.6x2.8x
Sun, 17 Dec 2023SEK 543.4bSEK 191.4b-SEK 942,084,132.0050.3x-576.8x2.8x
Tue, 14 Nov 2023SEK 471.3bSEK 190.3b-SEK 1,158,325,962.0049.9x-406.9x2.5x
Thu, 12 Oct 2023SEK 443.8bSEK 185.0b-SEK 2,013,777,426.0034x-220.4x2.4x
Sat, 09 Sep 2023SEK 452.7bSEK 185.7b-SEK 2,024,227,059.0036.6x-223.6x2.4x
Mon, 07 Aug 2023SEK 473.1bSEK 183.9b-SEK 1,034,178,130.0039.9x-457.5x2.6x
Wed, 05 Jul 2023SEK 485.5bSEK 179.3b-SEK 793,453,619.0045.6x-611.8x2.7x
Fri, 02 Jun 2023SEK 507.0bSEK 178.9b-SEK 585,070,238.0042.4x-866.5x2.8x
Sun, 30 Apr 2023SEK 518.4bSEK 176.0b-SEK 795,920,993.0035.3x-651.3x2.9x
Tue, 28 Mar 2023SEK 483.1bSEK 172.4b-SEK 1,400,658,692.0034.9x-344.9x2.8x
Thu, 23 Feb 2023SEK 494.1bSEK 170.3b-SEK 1,454,731,622.0037.5x-339.6x2.9x
Price to Earnings Ratio

-339.6x


Total Market Cap: SEK 494.1bTotal Earnings: -SEK 1,454,731,622.00Total Revenue: SEK 170.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -173.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.5x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-1.42%
Healthcare-2.77%
Biotech1.86%
Medical Equipment0.43%
Life Sciences-6.36%
Healthtech-7.24%
Healthcare Services-7.70%
Pharma-15.74%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 98.2x.
    • Analysts are expecting annual earnings growth of 21.2%, which is higher than its past year's earnings decline of 44.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 36% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 407.603.0%
+SEK 4.1b		29.0%PE294.8x
MCOV B MedicoverSEK 209.003.2%
+SEK 981.4m		0.2%PE38.5x
VIMIAN Vimian GroupSEK 27.845.9%
+SEK 815.1m		-40.6%PE44.5x
BONEX Bonesupport HoldingSEK 180.803.7%
+SEK 428.1m		-46.5%PE78.4x
IMP A SDB ImplanticaSEK 46.202.7%
+SEK 340.0m		13.7%PS623x

Latest News

VIMIAN
SEK 27.84
Vimian Group
7D
5.9%
1Y
-40.6%

Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
RAY B
SEK 185.40
RaySearch Laboratories
7D
2.7%
1Y
-30.0%

Earnings Update: RaySearch Laboratories AB (publ) (STO:RAY B) Just Reported And Analysts Are Trimming Their Forecasts

Feb 15
Earnings Update: RaySearch Laboratories AB (publ) (STO:RAY B) Just Reported And Analysts Are Trimming Their Forecasts
STIL
SEK 181.00
Stille
7D
24.0%
1Y
-27.6%

Stille AB Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 15
Stille AB Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
AMBEA
SEK 115.90
Ambea
7D
-17.4%
1Y
5.8%

Ambea (STO:AMBEA) Is Increasing Its Dividend To SEK2.65

Feb 15
Ambea (STO:AMBEA) Is Increasing Its Dividend To SEK2.65
BIOG B
SEK 103.70
BioGaia
7D
-4.9%
1Y
-20.3%
CAMX
SEK 553.50
Camurus
7D
-20.1%
1Y
-12.3%
MCAP
SEK 480.00
MedCap
7D
-6.1%
1Y
17.6%
MCOV B
SEK 209.00
Medicover
7D
3.2%
1Y
0.2%
ASKER
SEK 65.08
Asker Healthcare Group
7D
-18.7%
1Y
n/a
BONEX
SEK 180.80
Bonesupport Holding
7D
3.7%
1Y
-46.5%

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
ALIF B
SEK 138.10
AddLife
7D
-6.5%
1Y
-20.2%

Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings

Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings
GETI B
SEK 201.20
Getinge
7D
-1.0%
1Y
-5.2%

GETI B: Higher P/E Expectations Will Outrun Softer Margins And Dividend Uplift

Analysts have adjusted their price target on Getinge from SEK165.00 to about SEK171.00, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Getinge AB (publ) has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 per share previously, subject to approval (Key Developments).
SOBI
SEK 407.60
Swedish Orphan Biovitrum
7D
3.0%
1Y
29.0%
IMP A SDB
SEK 46.20
Implantica
7D
2.7%
1Y
13.7%
SECT B
SEK 181.70
Sectra
7D
-9.4%
1Y
-29.7%

SECT B: Cloud Contracts And Pathology Expansion Will Support Future Upside Potential

Analysts have reaffirmed their price target on Sectra at SEK 245.00, with only marginal tweaks to underlying model inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, supporting an unchanged view of fair value. What's in the News TUM Klinikum in Germany is expanding its Sectra enterprise imaging setup with pathology and ophthalmology modules under a five year contract covering up to 300,000 examinations per year, aimed at higher efficiency and closer collaboration across departments (Client announcement).
HNSA
SEK 40.00
Hansa Biopharma
7D
7.5%
1Y
76.1%

HNSA: US Kidney Transplant Approval Timing Will Drive Downside Risk

Analysts have nudged their price target for Hansa Biopharma to SEK 69, reflecting updated assumptions on growth, profitability and valuation multiples, supported by views that imlifidase underpins a more de-risked commercial profile across kidney transplantation, autoimmune disease and gene therapy. Analyst Commentary Recent Street research frames Hansa Biopharma as a company with a clearly defined lead asset and a focused commercial plan across kidney transplantation, autoimmune disease and gene therapy.